fidarestat has been researched along with 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid in 1 studies
| Studies (fidarestat) | Trials (fidarestat) | Recent Studies (post-2010) (fidarestat) | Studies (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) | Trials (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) | Recent Studies (post-2010) (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) |
|---|---|---|---|---|---|
| 97 | 3 | 33 | 1,541 | 16 | 580 |
| Protein | Taxonomy | fidarestat (IC50) | 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 0.13 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.15 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Demopoulos, VJ; Nicolaou, I | 1 |
1 other study(ies) available for fidarestat and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid
| Article | Year |
|---|---|
Substituted pyrrol-1-ylacetic acids that combine aldose reductase enzyme inhibitory activity and ability to prevent the nonenzymatic irreversible modification of proteins from monosaccharides.
Topics: Acetates; Aldehyde Reductase; Animals; Diabetes Mellitus; Enzyme Inhibitors; Female; Fructose; Male; Monosaccharides; Oxidation-Reduction; Proteins; Pyrroles; Rats; Rats, Inbred F344; Serum Albumin; Structure-Activity Relationship | 2003 |